Loading
A phase 2 trial of Abemaciclib and Temozolomide in ewing sarcoma, run by Eli Lilly and Company, active and no longer recruiting.
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma is a phase 2 interventional study registered as NCT05440786 by Eli Lilly and Company, with 46 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2025-01-15. Interventions recorded: Abemaciclib, Irinotecan and Temozolomide. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
46 enrolled.
95% CI 1.74 to 13.32; Figures from the ClinicalTrials.gov results section (first posted 2026-03-12), not from a publication · 95% CI 1.25 to 5.13
Source95% CI 9.17 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-03-12), not from a publication · 95% CI 5.13 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| PFS Assessed by BIRC by Frequentist Analysisprimary | Abemaciclib + Irinotecan +Temozolomide | 30 | 2.79 months | 0.639 (0.282 to 1.449) | 0.281 | link |
| Irinotecan +Temozolomide | 16 | 2.89 months | ||||
| Overall Survival (OS) | Abemaciclib + Irinotecan +Temozolomide | 30 | 21.21 months | 0.667 (0.255 to 1.745) | 0.406 | link |
| Irinotecan +Temozolomide | 16 | 6.94 months |
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors, Temozolomide and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), CDK4/6 inhibitors and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.